Clinical Trial Update: Effect of Lactobacillus Rhamnosus on Serum Uremic Toxins in Hemodialysis [NA]

View source ↗

Summary

A completed clinical trial evaluating whether supplementation with Lactobacillus rhamnosus alters serum uremic toxin levels in patients undergoing hemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Lactobacillus rhamnosus (Lactobacillus rhamnosus)

Snippet

Sponsor: nooshin dalili | Conditions: Hemodialysis Complication | NA | Status: COMPLETED